CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 72 enrolled
Drug / intervention
Halobetasol Propionate Lotion 0.05% +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01610596
NCT01610596Phase 2Completed
CompareCT.gov

A Double-blind, Randomized, Multicenter, Vehicle-Controlled Parallel Group Study to Determine the Efficacy and Safety of Halobetasol Propionate Lotion 0.05% in Subjects With Plaque Psoriasis Receiving Two Weeks of Treatment

Therapeutics, Inc.·interventional·Posted Jun 4, 2012·Updated May 13, 2016

In Brief

A Phase 2 clinical trial evaluating Halobetasol Propionate Lotion 0.05% and Placebo for Psoriasis and Plaque Psoriasis. Completed, enrolled 72 participants across 3 sites.

Detailed Summary

This is a double-blind, multicenter, vehicle-controlled, parallel group comparison study to determine and compare the efficacy and safety of HBP Lotion 0.05% and Vehicle Lotion applied twice daily for two weeks in subjects with moderate to severe plaque psoriasis. Eligible subjects will be randomized (1:1) to one of two treatment groups - HBP Lotion 0.05% or Vehicle Lotion. The maximum amount of test article to be applied per week should not exceed 50 grams.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis, Plaque Psoriasis
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJun 4, 2012
Enrollment StartNov 1, 2011
Primary CompletionFeb 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 14.1 years ago

Interventions

Halobetasol Propionate Lotion 0.05%drug

Apply twice daily for 1-2 weeks, not to exceed 50 grams per week

Placebodrug